Thermo Fisher Scientific (TMO) Receivables - Other (2018 - 2026)

Thermo Fisher Scientific has disclosed Receivables - Other across 9 years of filings, most recently posting $1.7 billion for Q1 2026.

• Quarterly Receivables - Other rose 23.28% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 23.28% YoY) and the FY2025 annual result came in at $1.7 billion, up 16.1% from the prior year.
• Receivables - Other improved to $1.7 billion in Q1 2026, from $1.7 billion in the prior quarter.
• Over five years, Receivables - Other peaked at $1.7 billion in Q1 2026 and troughed at $1.1 billion in Q2 2022.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2025 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other soared 54.46% — and 2025, when it decreased 3.94%.
• Tracing TMO's Receivables - Other over 5 years: stood at $1.3 billion in 2022, then grew by 9.98% to $1.4 billion in 2023, then decreased by 0.55% to $1.4 billion in 2024, then climbed by 16.1% to $1.7 billion in 2025, then grew by 1.08% to $1.7 billion in 2026.
• Business Quant data shows TMO's Receivables - Other at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.